AVM Biotechnology, Inc.

Seattle, WA

UEI
D29NFMS3DJJ8
CAGE
59W32
Primary NAICS
Not on record
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Woman Owned Small Business
  • Woman Owned Business
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
8226 23rd Ave NE, Seattle, WA 98115, USA
Website
avmbiotech.com
Founded
2008
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Immunomodulatory AVM0703 to bridge relapsed/refractory diffuse large b-cell lymphoma patients to car-t cell… R44CA310370 National Cancer Institute (NIH) $992,425
AVM0703 combined with non-hodgkin's lymphoma standard of care to enhance complete response rates without additional… R43CA271951 National Cancer Institute (NIH) $798,386
Expedited expansion cohort clinical trial for relapsed/refractory 'no-option' non-hodgkin's lymphoma/leukemia patients R44CA272096 National Cancer Institute (NIH) $2,999,997
A novel non-toxic preconditioning regimen for cancer cell therapy R43CA246896 National Cancer Institute (NIH) $224,770
Targeted lymphoablation as an alternative to hsct to cure T1D R44DK121634 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $4,598,094

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

Vendor Location Primary NAICS
Senex Biotechnology Inc. UEI G8XKMW3DYMQ6 Maynard, MA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Window Therapeutics, Inc. UEI JFLXDJ3ZY975 Boston, MA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Luminary Therapeutics, Inc. UEI MNKBAEZHWJS1 Minneapolis, MN 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Nanocan Therapeutics Corporation UEI MUW6XWEVLLN3 Forest Heights, MD 541713 Research and Development in Nanotechnology
PDX Pharmaceuticals Inc. UEI VTX7JRKLC3F5 Portland, OR 541713 Research and Development in Nanotechnology

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

AVM Biotechnology, Inc., registered in SAM.gov since 2008, is a woman-owned small business located in Seattle, Washington, focused on developing innovative immunomodulatory therapies for cancer treatment. The company specializes in developing proprietary pharmaceutical formulations, with a particular focus on addressing challenges in Non-Hodgkin's Lymphoma (NHL) treatment, specifically targeting diffuse large B-cell lymphoma (DLBCL). As a for-profit corporate entity, AVM Biotechnology has established itself as a promising biotechnology firm with a concentrated research and development approach in oncological therapeutics.

The company has secured multiple federal grant awards from the National Cancer Institute (NCI) under the Cancer Treatment Research program, focusing on developing AVM0703, a proprietary high-concentration dexamethasone sodium phosphate formulation designed to bridge treatment gaps for relapsed/refractory NHL patients. Their grant-funded projects aim to enhance cancer treatment strategies, including developing immunomodulatory therapies to stabilize tumor burden, improve patient outcomes, and provide alternatives for patients unable to immediately access chimeric antigen receptor T-cell (CAR-T) immunotherapy. The clinical research spans multiple institutional partners, including City of Hope, UCLA, Norton Cancer Institute, Levine Cancer Institute, and University of Texas Southwestern, with ongoing FDA-approved clinical trials exploring AVM0703's potential in treating lymphoid malignancies. The grants, ranging from $992,425 to support various research phases, demonstrate the company's commitment to advancing cancer treatment options for patients with limited therapeutic alternatives.

Quick answers

Is AVM Biotechnology, Inc. registered in SAM.gov?

Yes. AVM Biotechnology, Inc.'s SAM.gov registration is active through March 3, 2027.

What is AVM Biotechnology, Inc.'s most recent federal award?

AVM Biotechnology, Inc.'s most recent federal grant award is Immunomodulatory AVM0703 to bridge relapsed/refractory diffuse large b-cell lymphoma patients to car-t cell… (R44CA310370), from National Cancer Institute (NIH), on September 8, 2025.

On GovTribe

See AVM Biotechnology, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login